** Shares of drugmaker Abeona Therapeutics ABEO.O up 12.7% at $6.03 premarket
** ABEO says the U.S. FDA has approved its gene therapy for a rare skin disorder
** The gene therapy, called Zevaskyn, is approved to treat adult and pediatric patients with recessive dystrophic epidermolysis bullosa
** The current standard-of-care treatment is daily wound care and protective bandaging
** Company says the treatment is expected to be available in Q3 2025
** As of last close, ABEO shares down 4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.